Source-grounded facts extracted from MiNK Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
MiNK Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income net loss for the quarter ended December 31, 2025, was $2.6 million, or $0.56 per share.
“On March 31, 2026, MiNK Therapeutics, Inc. (the "Company") announced its financial results for the quarter and year ended December 31, 2025.”
Robert Kadlec was elected as Director at MiNK Therapeutics, Inc..
“On October 30, 2024, the Board of Directors (the “Board”) of MiNK Therapeutics Inc., ("MiNK") elected Dr. Robert Kadlec to become a Class II director of MiNK with an initial term that expires at MiNK's annual meeting of stockholders in 2026.”
Dr. Marc Van Dijk changed role as Chief Scientific Officer at MiNK Therapeutics, Inc..
“Dr. Marc Van Dijk will transition from his role as Chief Scientific Officer and assume the positions of Scientific Advisory Board Member and Strategic Consultant.”
MiNK Therapeutics, Inc. reported for the first quarter 2024 results: net income $3.8 million, or $0.11 per share, EPS $0.11 per share.
“Net loss for the first quarter of 2024 was $3.8 million, or $0.11 per share, compared to $5.7 million, or $0.17 per share, for the first quarter of 2023.”
MiNK Therapeutics, Inc. reported fourth quarter and full-year 2023 results: net income Net loss for the year ended December 31, 2023 was $22.5 million, or $0.65 per share, EPS $0.65.
“MiNK Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.